RAINBIO, INC.

Raleigh, NC · Founded 2020 · Biotech · Acquired

AAV gene therapy vector (RBIO-1) delivering IDUA cDNA to the cornea for treatment of mucopolysaccharidosis I corneal clouding

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
Raleigh, NC
Founded
2020
Latest Form D
$50K, Dec 2020
Total capital
$418K
Federal grants
$368K
1 award · 2022
Rank in peer group#397 of 502
Private capital raised
$50K
1 Form D · last Dec 2020
71 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

202020212022FEDERAL ↑EQUITY ↓Cumulative $418K$368K1st Form D$50K
202020212022FEDERAL ↑EQUITY ↓Cumulative $418K$368K1st Form D$50K

Latest events

  • Federal grantHealth and Human S · Phase I · Tolerability and Potency of Sequential and Repeated AAV Corneal Gene Therapy$368K
  • Private capital raisedForm D · SEC · 1st filing$50K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Matthew HirschResearcherDirector, PromoterLinked by $368K in grants as PI
  • Benjamin YerxaDirectorNamed in SEC Form D filings
  • Brian GilgerExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Frances MartinExecutive Officer, Director, PromoterNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Covira SurgicalSimilar federal contract value in Biotech · null in contracts
  • CHEMOSEN3D INCSimilar federal contract value in Biotech · null in contracts
  • Talapo TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • LACTIGA US INC.Similar federal contract value in Biotech · null in contracts
  • Topogen, IncSimilar federal contract value in Biotech · null in contracts
  • IATERION, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .